Immunomodulating options for liver transplant patients

Expert Review of Clinical Immunology

Volumn 8, Issue 6, 2012, Pages 565-578

  Zarrinpar, Ali ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibody therapy; calcineurin inhibitor; immune monitoring; immunosuppression; liver transplant; mTOR inhibitor; patient specific therapy; tolerance

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; STEROID;

END STAGE LIVER DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PERIOPERATIVE PERIOD; POST TREATMENT SURVIVAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ANTIBODIES; CALCINEURIN; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 84866648780     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.47     Document Type: Review

References (149)

1. Murray G, Holden R. Transplantation of kidneys, experimentally and in human cases. Am. J. Surg. 87(4), 508-515 (1954).
2. Calne RY, Rolles K, White DJ et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2(8151), 1033-1036 (1979).
3. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann. Intern. Med. 101(5), 667-682 (1984).
4. Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J. Gastroenterol. 15(34), 4225-4233 (2009).
5. Rasmussen A, Davies HF, Jamieson NV, Evans DB, Calne RY. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival. Transplantation 59(6), 919-921 (1995).
6. Kamada N, Davies HS, Roser B. Reversal of transplantation immunity by liver grafting. Nature 292(5826), 840-842 (1981).
7. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Hematol. 56(1), 23-46 (2005).
8. d'Apice AJ, Becker GJ, Kincaid-Smith P et al. A prospective randomized trial of low-dose versus high-dose steroids in cadaveric renal transplantation. Transplantation 37(4), 373-377 (1984).
9. Mazzaferro V, Rondinara GF, Rossi G et al. Milan multicenter experience in liver transplantation for hepatocellular carcinoma. Transplant. Proc. 26(6), 3557-3560 (1994).
10. Chen ZS, He F, Zeng FJ, Jiang JP, Du DF, Liu B. Early steroid withdrawal after liver transplantation for hepatocellular carcinoma. World J. Gastroenterol. 13(39), 5273-5276 (2007).
11. Henry SD, Metselaar HJ, Van Dijck J, Tilanus HW, Van Der Laan LJ. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann. N. Y. Acad. Sci. 1110, 439-447 (2007).
12. Vivarelli M, Burra P, La Barba G et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J. Hepatol. 47(6), 793-798 (2007).
13. Knight SR, Morris PJ. Steroid sparing protocols following nonrenal transplants; the evidence is not there. A systematic review and meta-analysis. Transpl. Int. 24(12), 1198-1207 (2011).
14. Segev DL, Sozio SM, Shin EJ et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 14(4), 512-525 (2008).
15. Sgourakis G, Radtke A, Fouzas I et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl. Int. 22(9), 892-905 (2009).
16. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl. Surg. 5(4 Suppl. 1), S107-S114 (1999).
17. Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 58(3), 452-463 (2009).
18. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A; UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 360(9340), 1119-1125 (2002).
19. Levy G, Grazi GL, Sanjuan F et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 12(10), 1464-1472 (2006).
20. Levy G, Villamil F, Samuel D et al.; LIS2T Study Group. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77(11), 1632-1638 (2004).
21. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349(10), 931-940 (2003).
22. Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl. Int. 22(1), 49-60 (2009).
23. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst. Rev. (4), CD005161 (2006).
24. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397(6719), 530-534 (1999).
25. Vivarelli M, Cucchetti A, Piscaglia F et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 11(5), 497-503 (2005).
26. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8(2), 128-135 (2002).
27. Baksh S, DeCaprio JA, Burakoff SJ. Calcineurin regulation of the mammalian G0/G1 checkpoint element, cyclin dependent kinase 4. Oncogene 19(24), 2820-2827 (2000).
28. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 357(9256), 609-610 (2001).
29. Jiménez-Pérez M, Lozano Rey JM, Marín García D, Olmedo Martín R, de la Cruz Lombardo J, Rodrigo López JM. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation. Transplant. Proc. 38(8), 2480-2481 (2006).
30. Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation 91(4), 470-478 (2011).
31. Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 10(1), 52-57 (2004).
32. Germani G, Pleguezuelo M, Villamil F et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am. J. Transplant. 9(8), 1725-1731 (2009).
33. Watson CJ, Friend PJ, Jamieson NV et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67(4), 505-509 (1999).
34. Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: what role in liver transplantation? J. Hepatol. 55(6), 1441-1451 (2011).
35. Dunkelberg JC, Trotter JF, Wachs M et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 9(5), 463-468 (2003).
36. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 10(10), 1301-1311 (2004).
37. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 9(10), 1079-1085 (2003).
38. Lam P, Yoshida A, Brown K et al. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig. Dis. Sci. 49(6), 1029-1035 (2004).
39. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5(11), 1298-1302 (1999).
40. Schiopu A, Wood KJ. Regulatory T cells: hypes and limitations. Curr. Opin. Organ Transplant. 13(4), 333-338 (2008).
41. Wang Z, Zhou J, Fan J et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 135(5), 715-722 (2009).
42. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2, 45 (2009).
43. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73(10), 1565-1572 (2002).
44. Schumacher G, Oidtmann M, Rosewicz S et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant. Proc. 34(5), 1392-1393 (2002).
45. Liang W, Wang D, Ling X et al. Sirolimusbased immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 18(1), 62-69 (2012).
46. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51(4), 1237-1243 (2010).
47. Zimmerman MA, Trotter JF, Wachs M et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 14(5), 633-638 (2008).
48. Schnitzbauer AA, Schlitt HJ, Geissler EK. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Transplantation 91(11), 1173-1176 (2011).
49. McKenna GJ, Trotter JF, Klintmalm E et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am. J. Transplant. 11(11), 2379-2387 (2011).
50. Huynh H, Chow KH, Soo KC et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. 13(7), 1371-1380 (2009).
51. Bilbao I, Sapisochin G, Dopazo C et al. Indications and management of everolimus after liver transplantation. Transplant. Proc. 41(6), 2172-2176 (2009).
52. Pérez T, Segovia R, Castro L, Roblero JP, Estela R. Conversion to everolimus in liver transplant patients with renal dysfunction. Transplant. Proc. 43(6), 2307-2310 (2011).
53. Fischer L, Klempnauer J, Beckebaum S et al. A Randomized, controlled study to assess the conversion from calcineurininhibitors to everolimus after liver transplantation-PROTECT. Am. J. Transplant (2012).
54. Feng X, Kajigaya S, Solomou EE et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 111(7), 3675-3683 (2008).
55. Soliman T, Hetz H, Burghuber C et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl. 13(7), 1039-1044 (2007).
56. Tector AJ, Fridell JA, Mangus RS et al. Promising early results with immunosuppression using rabbit antithymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl. 10(3), 404-407 (2004).
57. Mangus RS, Fridell JA, Vianna RM, Kwo PY, Chen J, Tector AJ. Immunosuppression induction with rabbit antithymocyte globulin (rATG) +-rituximab in 1000 liver transplants with long-term follow-up. Liver Transpl. 18(7), 786-795 (2012).
58. Berenguer M, Pons JA. rATG in liver transplantation: "all that glitters is not gold", but 1000 patients are so many to dazzle. Liver Transpl. 18(7), 755-760 (2012).
59. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 75(8), 1396-1399 (2003).
60. Richardson AJ, Higgins RM, Liddington M, Murie J, Ting A, Morris PJ. Antithymocyte globulin for steroid resistant rejection in renal transplant recipients immunosuppressed with triple therapy. Transpl. Int. 2(1), 27-32 (1989).
61. Benítez CE, Puig-Pey I, López M et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am. J. Transplant. 10(10), 2296-2304 (2010).
62. Liu CL, Fan ST, Lo CM et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 10(6), 728-733 (2004).
63. Hirose R, Roberts JP, Quan D et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 69(2), 307-311 (2000).
64. Goralczyk AD, Hauke N, Bari N, Tsui TY, Lorf T, Obed A. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology 54(2), 541-554 (2011).
65. Van Gelder T, Warlé M, Ter Meulen RG. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs 64(16), 1737-1741 (2004).
66. Li W, Carper K, Liang Y et al. Anti-CD25 mAb administration prevents spontaneous liver transplant tolerance. Transplant. Proc. 38(10), 3207-3208 (2006).
67. Li W, Kuhr CS, Zheng XX et al. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am. J. Transplant. 8(8), 1639-1651 (2008).
68. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl. Int. 19(9), 705-714 (2006).
69. Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 2(8401), 483-486 (1984).
70. Tzakis AG, Tryphonopoulos P, Kato T et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 77(8), 1209-1214 (2004).
71. Marcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 78(7), 966-971 (2004).
72. Levitsky J, Thudi K, Ison MG, Wang E, Abecassis M. Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl. 17(1), 32-37 (2011).
73. Vanrenterghem Y, Bresnahan B, Campistol J et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 91(9), 976-983 (2011).
74. Pescovitz MD. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection. Clin. Transplant. 20(1), 48-54 (2006).
75. Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat. Rev. Drug Discov. 10(9), 655-656 (2011).
76. Selzner N, Grant DR, Shalev I, Levy GA. The immunosuppressive pipeline: meeting unmet needs in liver transplantation. Liver Transpl. 16(12), 1359-1372 (2010).
77. Pribila JT, Quale AC, Mueller KL, Shimizu Y. Integrins and T cell-mediated immunity. Annu. Rev. Immunol. 22, 157-180 (2004).
78. Weaver TA, Charafeddine AH, Agarwal A et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat. Med. 15(7), 746-749 (2009).
79. Fung JJ, Bollinger JE, Miller C, Eghtesad B. Future prospects in immunosuppression for liver transplantation. Liver Transpl. 17(Suppl. 3), S54-S59 (2011).
80. Stotler CJ, Eghtesad B, Hsi E, Silver B. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. Blood 113(21), 5365-5366 (2009).
81. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibodymediated rejection. Am. J. Transplant. 9(1), 231-235 (2009).
82. Vincenti F, Kirk AD. What's next in the pipeline. Am. J. Transplant. 8(10), 1972-1981 (2008).
83. Klipa D, Mahmud N, Ahsan N. Antibody immunosuppressive therapy in solid organ transplant: Part II. MAbs 2(6), 607-612 (2010).
84. Karczewski M, Karczewski J, Poniedzialek B, Wiktorowicz K, Smietanska M, Glyda M. Distinct cytokine patterns in different states of kidney allograft function. Transplant. Proc. 41(10), 4147-4149 (2009).
85. Hribova P, Lacha J, Kotsch K et al. Intrarenal cytokine and chemokine gene expression and kidney graft outcome. Kidney Blood Press. Res. 30(5), 273-282 (2007).
86. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89(3), 277-284 (2010).
87. Flanagan ME, Blumenkopf TA, Brissette WH et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53(24), 8468-8484 (2010).
88. Budde K, Sommerer C, Becker T et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am. J. Transplant. 10(3), 571-581 (2010).
89. Friman S, Arns W, Nashan B et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am. J. Transplant. 11(7), 1444-1455 (2011).
90. Kovarik JM, Neuhaus P, Cillo U et al. Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients. Transpl. Int. 24(3), 276-283 (2011).
91. Hutchinson JA, Brem-Exner BG, Riquelme P et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl. Int. 21(8), 742-754 (2008).
92. Kemmer N, Neff G. Recipient-based approach to tailoring immunosuppression in liver transplantation. Transplant. Proc. 42(5), 1731-1737 (2010).
93. Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther. 42(12), 701-718 (2004).
94. Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African-American and white volunteers. Clin. Pharmacol. Ther. 68(5), 478-486 (2000).
95. Nagashima N, Watanabe T, Nakamura M, Shalabi A, Burdick JF. Decreased effect of immunosuppression on immunocompetence in African-Americans after kidney and liver transplantation. Clin. Transplant. 15(2), 111-115 (2001).
96. Maggard M, Goss J, Ramdev S, Swenson K, Busuttil RW. Incidence of acute rejection in African-American liver transplant recipients. Transplant. Proc. 30(4), 1492-1494 (1998).
97. MacPhee IA, Fredericks S, Tai T et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4(6), 914-919 (2004).
98. Lipshutz GS, Hiatt J, Ghobrial RM et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch. Surg. 142(8), 775-81; discussion 781 (2007).
99. Audet M, Piardi T, Panaro F et al. Liver transplantation in recipients over 65 yr old: a single center experience. Clin. Transplant. 24(1), 84-90 (2010).
100. Herrero JI, Lucena JF, Quiroga J et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am. J. Transplant. 3(11), 1407-1412 (2003).
101. Castle SC. Clinical relevance of age-related immune dysfunction. Clin. Infect. Dis. 31(2), 578-585 (2000).
102. Bradley BA. Rejection and recipient age. Transpl. Immunol. 10(2-3), 125-132 (2002).
103. Staatz CE, Tett SE. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. Drugs Aging 22(7), 541-557 (2005).
104. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 9(2), 130-137 (2003).
105. Feng S. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? Curr. Opin. Organ Transplant. 13(5), 506-512 (2008).
106. Shepherd RW, Turmelle Y, Nadler M et al.; SPLIT Research Group. Risk factors for rejection and infection in pediatric liver transplantation. Am. J. Transplant. 8(2), 396-403 (2008).
107. del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. 41(2), 115-135 (2002).
108. Busuttil RW, Farmer DG, Yersiz H et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann. Surg. 241(6), 905-916; discussion 916 (2005).
109. Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 15(Suppl. 2), S25-S34 (2009).
110. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am. J. Transplant. 10(4), 720-726 (2010).
111. López-Larramona G, Lucendo AJ, González-Castillo S, Tenias JM. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. World J. Hepatol. 3(12), 300-307 (2011).
112. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 12(12), 1813-1824 (2006).
113. Hurtova M, Duclos-Vallée JC, Johanet C et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl. 7(6), 556-558 (2001).
114. Bzowej N, Han S, Degertekin B et al.; National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl. 15(9), 1010-1020 (2009).
115. Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J. Hepatol. 22(3), 257-262 (1995).
116. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr. Opin. Infect. Dis. 17(4), 363-371 (2004).
117. Berenguer M. Hot topic in hepatitis C virus research: the type of immunosuppression does not matter. Liver Transpl. 17(Suppl. 3), S24-S28 (2011).
118. Trotter JF. Hot-topic debate on hepatitis C virus: the type of immunosuppression matters. Liver Transpl. 17(Suppl. 3), S20-S23 (2011).
119. Berenguer M, Aguilera V, Prieto M et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol. 44(4), 717-722 (2006).
120. Henry SD, Metselaar HJ, Lonsdale RC et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 131(5), 1452-1462 (2006).
121. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl. 8(1), 40-46 (2002).
122. Firpi RJ, Zhu H, Morelli G et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 12(1), 51-57 (2006).
123. ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 92(3), 334-340 (2011).
124. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 13(1), 21-29 (2007).
125. Martin P, Busuttil RW, Goldstein RM et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 10(10), 1258-1262 (2004).
126. Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am. J. Transplant. 11(8), 1676-1685 (2011).
127. Vivarelli M, Cucchetti A, La Barba G et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann. Surg. 248(5), 857-862 (2008).
128. Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary Pancreat Dis. Int. 10(3), 234-242 (2011).
129. Chinnakotla S, Davis GL, Vasani S et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 15(12), 1834-1842 (2009).
130. Raut V, Uemoto S. Management of ABO-incompatible living-donor liver transplantation: past and present trends. Surg. Today 41(3), 317-322 (2011).
131. Tanabe M, Kawachi S, Obara H et al. Current progress in ABO-incompatible liver transplantation. Eur. J. Clin. Invest. 40(10), 943-949 (2010).
132. Agopian VG, Kaldas FM, Hong JC et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann. Surg. (2010) (Epub ahead of print).
133. Remberger M, Sundberg B. Rabbitimmunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 90(7), 931-938 (2005).
134. Levitsky J. Next level of immunosuppression: drug/immune monitoring. Liver Transpl. 17(Suppl. 3), S60-S65 (2011).
135. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82(5), 663-668 (2006).
136. Xue F, Zhang J, Han L et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. Transplantation 89(5), 620-626 (2010).
137. Berglund D, Bengtsson M, Biglarnia A et al. Screening of mortality in transplant patients using an assay for immune function. Transpl. Immunol. 24(4), 246-250 (2011).
138. Cabrera R, Ararat M, Soldevila-Pico C et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl. 15(2), 216-222 (2009).
139. Hashimoto K, Miller C, Hirose K et al. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin. Transplant. 24(5), 701-708 (2010).
140. Cheng JW, Shi YH, Fan J et al. An immune function assay predicts posttransplant recurrence in patients with hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 137(10), 1445-1453 (2011).
141. Uemura T, Riley TR, Khan A et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin. Transplant. 25(1), E32-E37 (2011).
142. Sagoo P, Perucha E, Sawitzki B et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120(6), 1848-1861 (2010).
143. Fernandez LA, Tsuchida M, Manthei E et al. Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. Transpl. Immunol. 13(2), 147-154 (2004).
144. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl. Immunol. 17(2), 108-113 (2007).
145. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358(4), 353-361 (2008).
146. Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358(4), 362-368 (2008).
147. Brouard S, Mansfield E, Braud C et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl. Acad. Sci. USA 104(39), 15448-15453 (2007).
148. Ying L, Sarwal M. In praise of arrays. Pediatr. Nephrol. 24(9), 1643-1659; quiz 1655, 1659 (2009).
149. Martínez-Llordella M, Lozano JJ, Puig-Pey I et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J. Clin. Invest. 118(8), 2845-2857 (2008).